Company OXFORD BIOMEDICA Swiss Exchange

Equities

OXB

GB0006648157

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per Business

Sales per region

Sector Bio Therapeutic Drugs

Inactive Instrument

Oxford Biomedica plc is a United Kingdom-based cell and gene therapy research, development and bio-processing company. The Company is engaged in providing services to third parties, as well as performing internal research and development for its own purposes. It performs a range of analytical assays within its in-house quality check (QC) labs. The Company operates through two segments: Platform and Product. Platform segment is involved in bio-processing and processes development activities undertaken process by third parties, which is the partner programme for LentiVector and AAV CDMOs business. The segment also includes internal technology developments and technical intellectual property within the LentiVector platform. Product segment consists of the clinical and pre-clinical development of in vivo and ex vivo cell and gene therapy products (gene therapeutics), which are owned by the Company.

GBP in Million	2022	Weight	2023	Weight	Delta
Platform 99.9 %	140	99.9 %	89	99.9 %	-36.09%
Product 0.1 %	0	0.1 %	0	0.1 %	+50.00%

GBP in Million	2022	Weight	2023	Weight	Delta
United States 73.4 %	62	44.0 %	66	73.4 %	+6.76%
Europe 22.1 %	28	20.0 %	20	22.1 %	-29.45%
United Kingdom 4.4 %	50	35.7 %	4	4.4 %	-92.02%

Managers	Title	Age	Since
Frank Mathias CEO	Chief Executive Officer	62	27/23/27
Stuart Paynter DFI	Director of Finance/CFO	52	29/17/29
Frederic Roch Doliveux CHM	Chairman	68	24/20/24
James Miskin CTO	Chief Tech/Sci/R&D Officer	-	01/00/01
Matthew Treagus CTO	Chief Tech/Sci/R&D Officer	-	01/21/01
Sophia Bolhassan IRC	Investor Relations Contact	-	01/21/01
Natalie Walter IRO	Public Communications Contact	50	01/19/01
Lisa James HRO	Human Resources Officer	-	01/16/01
Sebastien Ribault PRN	Corporate Officer/Principal	-	01/22/01
Kyriacos Mitrophanous PRN	Corporate Officer/Principal	-	01/97/01

Members of the board	Title	Age	Since
Leone Patterson BRD	Director/Board Member	61	01/23/01
Frederic Roch Doliveux CHM	Chairman	68	24/20/24
Stuart Henderson BRD	Director/Board Member	66	01/16/01
Heather Elizabeth Preston BRD	Director/Board Member	58	15/18/15
Michael Hayden BRD	Director/Board Member	72	15/21/15
Dame Davies BRD	Director/Board Member	73	01/21/01
Catherine Moukheibir BRD	Director/Board Member	64	14/21/14
Stuart Paynter DFI	Director of Finance/CFO	52	29/17/29
Robert Ghenchev BRD	Director/Board Member	41	24/19/24
Namrata Patel BRD	Director/Board Member	-	13/22/13

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	100,000,296	80,810,643 ( 80.81 %)	0	80.81 %

Name	Equities	%	Valuation
Novo Nordisk Fonden 11.80 %	11,798,802	11.80 %	41 M p
Vulpes Investment Management Pte Ltd. 8.438 %	8,437,978	8.438 %	29 M p
Liontrust Investment Partners LLP 8.045 %	8,044,568	8.045 %	28 M p
Compagnie Merieux Alliance SAS 6.149 %	6,149,374	6.149 %	21 M p
M&G Investment Management Ltd. 5.068 %	5,067,751	5.068 %	18 M p
Global Alpha Capital Management Ltd. 3.881 %	3,880,863	3.881 %	13 M p
Nine Ten Partners LP 3.387 %	3,387,228	3.387 %	12 M p
Serum Institute Life Sciences Pvt Ltd. 3.383 %	3,382,950	3.383 %	12 M p
Hargreaves Lansdown Asset Management Ltd. 3.031 %	3,031,200	3.031 %	10 M p
Vitruvian Partners LLP 3.005 %	3,004,567	3.005 %	10 M p

Oxford Biomedica Plc

Windrush Court Transport Way

OX4 6LT, Oxford

+44 1865 783 000

http://www.oxfordbiomedica.co.uk

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+12.30%	116B
REGENERON PHARMACEUTICALS, INC.	+12.15%	106B
BIONTECH SE	-8.14%	23.89B
ARGENX SE	-1.69%	21.58B
GENMAB A/S	-10.60%	18.96B
WUXI APPTEC CO., LTD.	-41.25%	16.96B
BEIGENE, LTD.	-15.33%	16.33B
NEUROCRINE BIOSCIENCES, INC.	+5.80%	14.14B
SAREPTA THERAPEUTICS, INC.	+28.03%	12.02B

Bio Therapeutic Drugs